53 related articles for article (PubMed ID: 23150918)
1. Duloxetine, pregabalin, and duloxetine plus gabapentin for diabetic peripheral neuropathic pain management in patients with inadequate pain response to gabapentin: an open-label, randomized, noninferiority comparison.
Tanenberg RJ; Irving GA; Risser RC; Ahl J; Robinson MJ; Skljarevski V; Malcolm SK
Mayo Clin Proc; 2011 Jul; 86(7):615-26. PubMed ID: 21719618
[TBL] [Abstract][Full Text] [Related]
2. Career lifetime advances and key developments: diabetes.
Baglioni P; Govindan J; Khan A
Clin Med (Lond); 2007 Jun; 7(3):303-4. PubMed ID: 17639617
[No Abstract] [Full Text] [Related]
3. Healthcare Costs and Medication Adherence Among Patients with Fibromyalgia: Combination Medication vs. Duloxetine, Milnacipran, Venlafaxine, and Pregabalin Initiators.
Marlow NM; Simpson KN; Vaughn IA; Jo A; Zoller JS; Short EB
Pain Pract; 2018 Feb; 18(2):154-169. PubMed ID: 28419725
[TBL] [Abstract][Full Text] [Related]
4. Pregabalin and amitriptyline as first-line drugs among patients with painful peripheraldiabetic neuropathy: a systematic review and meta-analysis.
Alhowiti AM; Mirghani HO
Eur Rev Med Pharmacol Sci; 2024 May; 28(10):3598-3606. PubMed ID: 38856135
[TBL] [Abstract][Full Text] [Related]
5. Impact of potential pregabalin or duloxetine drug-drug interactions on health care costs and utilization among Medicare members with fibromyalgia.
Ellis JJ; Sadosky AB; Ten Eyck LL; Cappelleri JC; Brown CR; Suehs BT; Parsons B
Clinicoecon Outcomes Res; 2014; 6():389-99. PubMed ID: 25339847
[TBL] [Abstract][Full Text] [Related]
6. Healthcare Economics of High Frequency Spinal Cord Stimulation for Painful Diabetic Peripheral Neuropathy.
Rajkumar S; Venkatraman V; Zidanyue Yang L; Parente B; Lee HJ; Lad SP
J Diabetes Sci Technol; 2024 May; 18(3):635-643. PubMed ID: 36314587
[TBL] [Abstract][Full Text] [Related]
7. Diabetic Peripheral Neuropathy: Prevention and Treatment.
Bragg S; Marrison ST; Haley S
Am Fam Physician; 2024 Mar; 109(3):226-232. PubMed ID: 38574212
[TBL] [Abstract][Full Text] [Related]
8. A Brief Review on the Novel Therapies for Painful Diabetic Neuropathy.
Basem JI; Bah FN; Mehta ND
Curr Pain Headache Rep; 2023 Sep; 27(9):299-305. PubMed ID: 37392335
[TBL] [Abstract][Full Text] [Related]
9. Channeling of New Neuropsychiatric Drugs-Impact on Safety and Effectiveness Studies.
Abraham DS; Nguyen TPP; Blank LJ; Thibault D; Gray SL; Hennessy S; Leonard CE; Weintraub D; Willis AW
Neurotherapeutics; 2023 Mar; 20(2):375-388. PubMed ID: 36864331
[TBL] [Abstract][Full Text] [Related]
10. The hidden costs of painful diabetic neuropathy revealed.
Smith AG; Živković S
Neurol Clin Pract; 2020 Feb; 10(1):3-4. PubMed ID: 32185100
[No Abstract] [Full Text] [Related]
11. Adding pregabalin or gabapentin for the management of community-treated patients with painful diabetic peripheral neuropathy: a comparative cost analysis.
Sicras A; Rejas J; Navarro R; Planas A
Clin Drug Investig; 2013 Nov; 33(11):825-35. PubMed ID: 24085589
[TBL] [Abstract][Full Text] [Related]
12. Challenging the catechism of therapeutics for chronic neuropathic pain: Targeting CaV2.2 interactions with CRMP2 peptides.
Feldman P; Khanna R
Neurosci Lett; 2013 Dec; 557 Pt A(0 0):27-36. PubMed ID: 23831344
[TBL] [Abstract][Full Text] [Related]
13. Identification of patients with painful diabetic peripheral neuropathy who have a favorable cost profile with pregabalin treatment.
Udall M; Mardekian J; Cabrera J
Pain Pract; 2013 Jul; 13(6):476-84. PubMed ID: 23150918
[TBL] [Abstract][Full Text] [Related]
14. Health care costs in patients with painful diabetic peripheral neuropathy prescribed pregabalin or duloxetine.
Burke JP; Sanchez RJ; Joshi AV; Cappelleri JC; Kulakodlu M; Halpern R
Pain Pract; 2012 Mar; 12(3):209-18. PubMed ID: 21676163
[TBL] [Abstract][Full Text] [Related]
15. Retrospective evaluation of clinical characteristics, pharmacotherapy and healthcare resource use among patients prescribed pregabalin or duloxetine for diabetic peripheral neuropathy in usual care.
Gore M; Zlateva G; Tai KS; Chandran AB; Leslie D
Pain Pract; 2011; 11(2):167-79. PubMed ID: 20723096
[TBL] [Abstract][Full Text] [Related]
16. Costs of pregabalin or gabapentin for painful diabetic peripheral neuropathy.
Udall M; Harnett J; Mardekian J
J Med Econ; 2012; 15(2):361-70. PubMed ID: 22181052
[TBL] [Abstract][Full Text] [Related]
17. Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis.
van Nooten F; Treur M; Pantiri K; Stoker M; Charokopou M
Clin Ther; 2017 Apr; 39(4):787-803.e18. PubMed ID: 28365034
[TBL] [Abstract][Full Text] [Related]
18. Pregabalin for painful diabetic peripheral neuropathy: strategies for dosing, monotherapy vs. combination therapy, treatment-refractory patients, and adverse events.
Juhn MS; Parsons B; Varvara R; Sadosky A
Curr Med Res Opin; 2015 May; 31(5):1017-26. PubMed ID: 25772233
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
